

Herantis Pharma Plc: Managers' transactions – Inveni Life Sciences Fund I Ky

Herantis Pharma Plc

Company release, 5 April 2022 at 2:30 p.m. EEST

Herantis Pharma Oyj - Managers' Transactions

Person subject to the notification requirement

Name: Inveni Life Sciences Fund I Ky

Position: Closely associated person

(X) Legal person

(1): Person Discharging Managerial Responsibilities In Issuer

Name: Aki Prihti

Position: Member of the Board

Issuer: Herantis Pharma Oyj

LEI: 743700W4CQVYAT3WKK38

Notification type: INITIAL NOTIFICATION

Reference number: 12550/4/10

Transaction date: 2022-04-01

Venue not applicable

Instrument type: SHARE

ISIN: FI4000087861

Nature of the transaction: OTHER

Description: Inveni Life Sciences Fund I Ky is a limited partnership, which distributes the shares in question to its partners without payment.

Transaction details

(1): Volume: 57195 Unit price: 0 N/A

(2): Volume: 28597 Unit price: 0 N/A

(3): Volume: 14299 Unit price: 0 N/A

(4): Volume: 7149 Unit price: 0 N/A

(5): Volume: 7149 Unit price: 0 N/A

(6): Volume: 2574 Unit price: 0 N/A

(7): Volume: 171 Unit price: 0 N/A

Aggregated transactions

(7): Volume: 117134 Volume weighted average price: 0 N/A

Transaction date: 2022-03-31

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000087861

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 411000 Unit price: 1.5 EUR

Aggregated transactions

(1): Volume: 411000 Volume weighted average price: 1.5 EUR

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel.: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

Herantis Pharma Plc

Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson's Disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the ability to be delivered to the brain via subcutaneous administration.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit <https://www.herantis.com>.